Jump to content

Tovetumab

Edit links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DMacks (talk | contribs) at 23:53, 23 June 2020 (Remove malformatted |molecular_weight= when infobox can autocalculate it, per Wikipedia talk:WikiProject Pharmacology#Molecular weights in drugboxes (via WP:JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Tovetumab
Monoclonal antibody
Type?
SourceHuman
TargetPDGFRA
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6400H9906N1726O2002S54
Molar mass144792.97 g·mol−1

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer.[1] It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.[2]

This drug was developed by MedImmune, LLC.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
  2. ^ http://adisinsight.springer.com/drugs/800015253
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Tovetumab&oldid=964170398"